LivaNova PLC $LIVN Position Lessened by P2 Capital Partners LLC

P2 Capital Partners LLC lessened its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 3.9% in the third quarter, Holdings Channel.com reports. The fund owned 493,902 shares of the company’s stock after selling 20,000 shares during the period. LivaNova comprises approximately 5.0% of P2 Capital Partners LLC’s portfolio, making the stock its 7th largest holding. P2 Capital Partners LLC’s holdings in LivaNova were worth $25,871,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LIVN. Primecap Management Co. CA boosted its holdings in LivaNova by 0.7% in the second quarter. Primecap Management Co. CA now owns 4,641,352 shares of the company’s stock valued at $208,954,000 after acquiring an additional 32,942 shares in the last quarter. Artisan Partners Limited Partnership raised its holdings in LivaNova by 94.5% in the 3rd quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock worth $127,129,000 after purchasing an additional 1,179,436 shares in the last quarter. AQR Capital Management LLC raised its holdings in LivaNova by 30.5% in the 2nd quarter. AQR Capital Management LLC now owns 2,049,820 shares of the company’s stock worth $92,201,000 after purchasing an additional 478,525 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of LivaNova by 6.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,721,173 shares of the company’s stock worth $90,154,000 after purchasing an additional 106,889 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of LivaNova by 1.3% in the 2nd quarter. Geode Capital Management LLC now owns 1,429,740 shares of the company’s stock worth $64,374,000 after purchasing an additional 18,551 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

LIVN has been the topic of a number of research reports. Robert W. Baird set a $75.00 target price on shares of LivaNova in a research note on Tuesday, December 16th. Needham & Company LLC increased their price target on shares of LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Mizuho raised their price objective on shares of LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Piper Sandler reaffirmed an “overweight” rating and set a $85.00 price objective on shares of LivaNova in a research report on Thursday, February 19th. Finally, Barclays upped their target price on LivaNova from $67.00 to $73.00 and gave the stock an “equal weight” rating in a report on Friday, February 27th. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $74.78.

LivaNova Stock Performance

Shares of LIVN stock opened at $58.46 on Friday. The company’s fifty day moving average price is $65.00 and its 200-day moving average price is $59.73. The stock has a market cap of $3.20 billion, a PE ratio of -13.11 and a beta of 0.92. The company has a current ratio of 1.36, a quick ratio of 1.16 and a debt-to-equity ratio of 0.29. LivaNova PLC has a 12 month low of $32.48 and a 12 month high of $71.92.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.80 by $0.06. LivaNova had a negative net margin of 17.46% and a positive return on equity of 16.54%. The company had revenue of $360.86 million during the quarter, compared to analyst estimates of $354.31 million. During the same period last year, the business earned $0.81 EPS. LivaNova’s quarterly revenue was up 12.2% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. On average, equities analysts expect that LivaNova PLC will post 2.85 EPS for the current fiscal year.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.